Determinants and prognostic role of BNP in central Africans with congestive heart failure

2^nd World Congress on Biomarkers & Clinical Research

12-14 September 2011 Baltimore, USA

Longo-Mbenza B, Forka AC, Mouzenzo CM and Kianu Phanzu B

Posters: J Mol Biomark Diagn

Abstract :

B-type natriuretic peptide (BNP) is one of the most reliable biomarkers enabling a rapid bedside diagnosis and prognosis of congestive heart failure (CHF) in developed countries. Data related to BNP in sub-Saharan Africa is still lacking due to cost constraints. Th e aim of this study was to determine potential relationships between epidemiological features, symptoms, cardiometabolic risk factors, antioxidant biomarkers, white cell count, case fatality and BNP measurements. In univariate analysis, males, urban residences, excessive alcohol intake, coronary heart disease, dry cough, NYHA class 3-4 and mortality were defi ned by signifi cant and higher BNP levels. In bivariate analysis, neutrophils (r=0.286; P=0.047), total bilirubin (r=0.480; P?0.0001), direct bilirubin (r= 0.465; P?0.001), uric acid (r= 0.354; P=0.003), systolic blood pressure (r=-0.226; P=0.029) BUN (r=0.320; P=0.005) and sodium(r=-0.580; P=0.028) showed signifi cant correlations with BNP levels, respectively. In multiple linear regression analysis and aft er adjusting for confounding factors, the independent determinants explaining 99.1% of variations (adjusted R2) of BNP levels were BUN, neutrophils and uric acid. Th e optimal cut-off point of BNP≥800 pg/mL obtained by ROC curve (AUC=0.819 95% CI0.710- 0.937, SE=0.061; P=0.003, sensitivity= 97.5% and specifi city=75.8%, conferred a relative Risk of case fatality =16.9 95% CI 2.2-31.3; P?0.001). Th us in countries with limited resources, the equation Y(BNP)=-4247 + 0.630* BUN + 0.552* neutrophils +0.287* uric acid and BNP≥ 800 pg/mL should be validated in large studies for the CHF management

Biography :

Benjamin B. Benjamin has received his MD, PhD in pathophysiology and MMed in Internal Medicine from the Bukarest Medical Institute (Romania), MSc in Cardiology and PhD in Cardiology at the Free University of Brussels (Belgium). He is a former Fulbright Scholar and visiting Professor in Clinical Pharmacology/ Hypertension at the Institute of Lipid research, Baylor College of medicine, Houston (USA). He served for 30 years as chief of cardiology, Executive Dean of Faculty of Medicine and Deputy Vice-Chancellor at the University of Kinshasa, Democratic Republic of Congo. He is a member of 30 scientifi c societies, including: American Heart Association, American Diabetes Association, and American College of Cardiology, European Society of Cardiology and Pan-African society of Cardiology. He obtained a certifi cate in cardiovascular Epidemiology (Netherlands), Ethics (NIH), Bioethics (Oklahoma University) and Molecular genetics (Belgium, Italy). His original research was focused on elucidating the pathophysiological mechanisms of toxic myocarditis and immune-allergic cardiomyopathies. From 1980s until present, most of his research works are related to infl ammatory states, oxidative stress, molecular biology, genetics, biomarkers and environmental impacts in Atherosclerosis, HIV/AIDS-related cardiac lesions, deafness (discovery of genes) and co-expression of genes in Pancreas. In addition to his role as clinician, lecturer, academic leader mentor, WHO expert and UN/Climate change Expert, he has been a very productive scientist: Supervisor of more than 10 PhD theses, 25 MSc theses, and 100 mini-dissertations, and over 300 papers published under his supervision. He is currently Research Champion professor at the Faculty of Health sciences, Walter Sisulu University, Mthatha, South Africa